CLINICAL TRIALS PROFILE FOR GLYBURIDE; METFORMIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for glyburide; metformin hydrochloride
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00035542 ↗ | A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. | Completed | Bristol-Myers Squibb | Phase 3 | 2001-12-01 | The purpose of this clinical research study is to see if Glucovance, a medication currently approved for use in adults with type 2 diabetes, can control type 2 diabetes safely and effectively in children 9 to 16 years of age. |
NCT00035568 ↗ | A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes | Completed | Bristol-Myers Squibb | Phase 4 | 2002-02-01 | The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes. |
NCT00194896 ↗ | Preferred Treatment of Type 1.5 Diabetes | Completed | GlaxoSmithKline | N/A | 2000-02-01 | The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide. |
NCT00194896 ↗ | Preferred Treatment of Type 1.5 Diabetes | Completed | Seattle Institute for Biomedical and Clinical Research | N/A | 2000-02-01 | The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide. |
NCT00194896 ↗ | Preferred Treatment of Type 1.5 Diabetes | Completed | University of Washington | N/A | 2000-02-01 | The purpose of this research was to test whether one treatment was superior over another in the management of type 1.5 diabetes. Specifically we tested recently diagnosed antibody positive type 2 diabetic patients to determine whether treatment with rosiglitazone results in greater preservation of beta cell function compared to treatment with glyburide. |
NCT00232583 ↗ | Preservation of Beta-cell Function in Type 2 Diabetes Mellitus | Completed | University of Texas Southwestern Medical Center | N/A | 2003-11-01 | The study evaluates the rate beta-cell function decline in newly diagnosed type 2 diabetic patients on two different treatment regimens: insulin and metformin versus glyburide, metformin and pioglitazone. |
NCT00279045 ↗ | Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide | Completed | GlaxoSmithKline | Phase 3 | 2000-01-03 | The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for glyburide; metformin hydrochloride
Condition Name
Clinical Trial Locations for glyburide; metformin hydrochloride
Trials by Country
Clinical Trial Progress for glyburide; metformin hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for glyburide; metformin hydrochloride
Sponsor Name